Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 17, 2009

DrStockPick.com Stock Report!

PWRM, NGSX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday November 17, 2009 are:

**************************************************************

NGSX, NeurogesX, Inc.

NGSX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.

** The U.S. Food and Drug Administration (FDA) has approved NGSX’s Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia, the nerve pain which can follow an attack of shingles.

NGSX’s Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced

...

On the very first day of the week, Depomed Inc has come out with good news that their new shingles pain drug has met the study goal. Depomed has announced that they have achieved success in the late stage clinical trial of a drug that will be used for the treatment of pain following viral infection shingles. The news of this success had a straight impact on Depomed’s shares and it went up immediately after the news was announced.

Earlier in the session Depomed stocks advanced around $1.35 which is around 30.6 percent, later it went up to $5.76 and finally the shares peaked up to $6.21 which is their highest price since June 2006. Approximately around 288,000 shares were traded on an average in one single day and more

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday September 22, 2009

DrStockPick.com Stock Report!

**************************************************************

The Carbon Disclosure Project, which holds the largest database of corporate climate change information in the world, has recognized Air Products’ (NYSE: APD) approach to climate change disclosure and named the company to its Leadership Index for 2009.

Flushing Financial Corporation (Nasdaq:FFIC), the parent holding company for Flushing Savings Bank, announced today that it has completed its public offering of 8,317,400 shares of common stock at a price of $11.50 per share. The net proceeds of the

...

We are initiating coverage of Inhibitex (INHX) with a ‘Neutral’ rating and $2 price target. Our neutral rating stems from the very early-stage nature of the company’s pipeline -- leading candidate FV-100 is currently in phase II testing -- and the potential dilution risk coming from cash-raising activities later in 2009 or in 2010. Nevertheless, Inhibitex does have significant long-term upside potential based on the outcome of the ongoing phase II program for FV-100 and the movement of INH-189 into a phase I program. Data from the phase II FV-100 program is expected around the middle of 2010.  Data from a phase I proof-of-concept program on INH-189 is expected late 2010 / early 2011. Potential catalysts for the stock also include phase II or partnership news on Pharmasset’s PSI-7851 or Idenix’ IDX-184 phase II HCV phosphoramidate candidates. FV-100 a Game-Changer Inhibitex's lead development candidate, FV-100, ...

Yesterday, Valeant Pharmaceuticals International (VRX) announced the failure of its drug candidate, retigabine, in a mid-stage study. The trial evaluated retigabine for pain associated with postherpetic neuralgia (PHN), which is common in shingles. The company’s shares closed down 8.5% at $ 24.85.

Retigabine was tested in 187 PHN patients versus placebo for a period of up to ten weeks in approximately 50 locations. The drug was administered once daily in doses of 300 mg to 900 mg. In the final week, patients rated their pain on a scale of zero to ten. While retigabine was generally well tolerated, the study failed to meet its pre-specified primary efficacy endpoint. Valeant is analyzing the data further.

Shingles is an acute infection caused by herpes zoster, the same virus that causes chickenpox. It is characterized by great pain and involves inflammation of sensory nerves. It causes numbness and itching followed by

...

US stocks started the holiday-shortened trading week on a positive note as energy, technology and industrial shares pulled equity markets higher.  Although stocks seesawed in early trading, a gain in oil prices buoyed sentiments on the Street and investors raced to put money in the stock market. 

The Down Jones industrial average advanced 91 points or 1.1% and the S&P 500 increased 0.9%.  NASDAQ edged up 0.3%.  Volume on the NYSE was light with only 1.07 billion shares exchanging hands and advancing issues outpacing declining stocks by a three-to-two margin.  The measure of market volatility, the CBOE Vix, retreated 2.2% to 25.35%, its lowest level since mid-September.  Treasury prices jumped, with the yield on the benchmark 10-year note declining to 3.48%.  Crude prices jumped to more than $71 per barrel on higher demand expectations and reports that Nigerian militants partly shut down an offshore oil facility.    

Trading

...

Initial Jobless Claims rise…  PPI does too!  Euros get hung out on a line…  Gold makes a comeback! And Now… Today’s Pfennig!

Good day… And a Thunderin’ Thursday to you! It may not be Thunderin’ where you are, but apparently it was yesterday in my little river town, as I heard we had some shingles blow off… And… It certainly is Thunderin’ over in the Eurozone this morning, I’ll tell you why in a minute. So, let’s get going don’t want to get caught in any of that Thunder!

I finished the last of my 3 presentations yesterday, and called it quits, as far

...

The Investment U Conference Wrap-Up: “Don’t Miss Your Million Dollar Opportunity”

by Dr. Scott Brown, Education Director

It was quite a week at the Investment U Conference in sunny St. Petersburg. It’s been a few days and I’m still a little exhausted at the sheer amount of information covered.

Over the past week we’ve discussed gold, emerging markets and foreign currency Exchanges. In addition we’ve discussed options strategies, commodities, small caps, biotechs and the state of our economy. And yet we’ve really just scratched the surface of the kind of useful, actionable information given out…

There’s a lot that we’ve missed.

And if you weren’t there, then you have no way of knowing what the insiders are thinking, you have no way of knowing if you have just passed over the next big thing - those “million dollar investments” we all dream of.

I highly encourage you to purchase the audio

...

Abbott Labs Still Expects TriLipix Approval in 4Q08 Despite an unknown delay from the FDA on TriLipix, Abbott Labs (ABT) still expects approval before year-end. Other updates include a three month delay for Hologic (HOLX) and KV Pharma (KV-A) for Gestiva and a NDA filing yesterday for NeurogesX (NGSX) for its capsaicin skin patch (NGX-4010) in the treatment of post-herpetic neuralgia (nerve pain following shingles infection).